+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Forteo"

From
Postmenopausal Osteoporosis Treatment Market Report 2025 - Product Thumbnail Image

Postmenopausal Osteoporosis Treatment Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Teriparatide- Biosimilar Insight, 2022 - Product Thumbnail Image

Teriparatide- Biosimilar Insight, 2022

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Disease Analysis: Osteoporosis - Product Thumbnail Image

Disease Analysis: Osteoporosis

  • Report
  • March 2021
  • 48 Pages
  • Global
Forteo - API Insight, 2022 - Product Thumbnail Image

Forteo - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
  • 6 Results (Page 1 of 1)
Loading Indicator

Forteo is a drug used to treat osteoporosis, a condition characterized by low bone density and increased risk of fractures. It is a recombinant human parathyroid hormone (PTH) analog, which stimulates new bone formation and increases bone mineral density. It is used to treat postmenopausal women, men with osteoporosis, and those with glucocorticoid-induced osteoporosis. Forteo is part of the Endocrine and Metabolic Disorders Drugs market, which includes drugs used to treat conditions such as diabetes, obesity, and thyroid disorders. These drugs are used to regulate hormones and metabolism, and can be administered orally, intravenously, or topically. Companies in the Forteo market include Eli Lilly, Novartis, Merck, and Pfizer. Show Less Read more